Wall Street analyst estimates for Tenet Healthcare Corporation (THC): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Tenet Healthcare Corporation operates as a broad-ranging provider of health solutions. The company organizes its operations across three main divisions: Hospital Operations and Other, Ambulatory Care, and Conifer. Within its network of acute care facilities, Tenet delivers a full spectrum of essential services. These include core hospital functions such as operating and recovery suites, radiology and respiratory therapy, clinical laboratories, and on-site pharmacies.
Consensus price target
$288.00 (+6 % vs price $270.57)
between $265.00 and $308.00 · 14 targets published in the last quarter
Closing price, Oct 29
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $22.2B | $22.1B – $22.4B | $21.20 | 12 |
| 2027E | $22.5B | $22.2B – $23.2B | $21.07 | 12 |
| 2028E | $23.6B | $23.0B – $24.5B | $23.11 | 5 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 26 |
| Hold | 6 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 32 |
| Avg rating (−2 sell to +2 buy) | 0.81 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-29 | $4.68 | ||
| 2026-07-23 | $6.12 | $4.26 | +43.7% |
| 2026-04-30 | $4.82 | $4.17 | +15.6% |
| 2026-02-11 | $4.70 | $4.07 | +15.5% |
| 2025-10-28 | $3.70 | $3.34 | +10.8% |
| 2025-07-22 | $4.02 | $2.87 | +40.1% |
| 2025-04-29 | $4.36 | $3.12 | +39.7% |
| 2025-02-12 | $3.44 | $2.95 | +16.6% |
Valuation Ratios
| P/E Ratio | 7.85 |
| Price / Book | 4.81 |
| EV / EBITDA | 6.46 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.62B | $19.18B | $18.31B | $18.48B | $17.64B | $19.48B | $19.17B | $20.55B | $20.66B | $21.31B |
| Cost of Revenue | $12.48B | $12.38B | $11.65B | $11.77B | $11.41B | $12.22B | $12.13B | $12.74B | $12.46B | $3.78B |
| Gross Profit | $7.14B | $6.79B | $6.66B | $6.71B | $6.23B | $7.27B | $7.05B | $7.80B | $8.21B | $17.53B |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $315.0M | 0 | 0 | $344.0M | $403.0M | $412.0M | $412.0M | $418.0M | $8.80B | $8.71B |
| Operating Expenses | $5.89B | $5.68B | $5.02B | $5.18B | $4.24B | $4.40B | $4.71B | $5.29B | $2.25B | $14.09B |
| Operating Income | $1.25B | $1.11B | $1.64B | $1.54B | $1.99B | $2.87B | $2.33B | $2.51B | $5.96B | $3.44B |
| EBITDA | $2.08B | $1.80B | $2.44B | $2.15B | $2.53B | $3.67B | $3.08B | $3.39B | $6.89B | $4.48B |
| Interest Expense | $979.0M | $1.03B | $1.00B | $985.0M | $1.00B | $923.0M | $890.0M | $901.0M | $826.0M | $821.0M |
| Pre-tax Income | $248.0M | -$101.0M | $629.0M | $320.0M | $671.0M | $1.89B | $1.34B | $1.62B | $5.25B | $2.80B |
| Income Tax | $67.0M | $219.0M | $173.0M | $160.0M | -$97.0M | $411.0M | $344.0M | $306.0M | $1.18B | $433.0M |
| Net Income | -$192.0M | -$704.0M | $104.0M | -$215.0M | $399.0M | $914.0M | $411.0M | $611.0M | $3.20B | $1.41B |
| EPS | $-1.93 | $-7.00 | $1.09 | $-2.24 | $3.80 | $8.55 | $3.84 | $6.01 | $33.02 | $15.61 |
| EPS (Diluted) | $-1.93 | $-7.00 | $1.07 | $-2.24 | $3.75 | $8.42 | $3.79 | $5.71 | $32.70 | $15.49 |
| Shares Outstanding (Diluted) | 99.3 M | 100.6 M | 103.9 M | 103.4 M | 106.3 M | 108.6 M | 110.5 M | 104.8 M | 97.9 M | 90.8 M |
Price
| Price | $270.57 (closing price, October 29, 2026) |
| Market Cap | $21.8B |
| Exchange | NYSE |
| Country | US |
Related companies: SGRY · HCA · UHS · CON
Explore sector: Healthcare · Medical - Care Facilities
More sections of THC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks